1 March 2011 Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard Second Edition This standard provides protocols and related quality control parameters and interpretive criteria for the susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. A standard for global application developed through the Clinical and Laboratory Standards Institute consensus process.
2 Clinical and Laboratory Standards Institute Setting the standard for quality in clinical laboratory testing around the world. The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability. Consensus Process Consensus the substantial agreement by materially affected, competent, and interested parties is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement. Commenting on Documents CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care. CLSI s consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate. Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts. Appeals Process If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Standards Development Policies and Process document. All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request. Get Involved Volunteer! Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe. For further information on committee participation or to submit comments, contact CLSI. Clinical and Laboratory Standards Institute 950 West Valley Road, Suite 2500 Wayne, PA USA P: F:
3 ISBN Vol. 31 No. 5 Replaces M24-A ISSN Vol. 23 No. 18 Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard Second Edition Volume 31 Number 5 Gail L. Woods, MD Barbara A. Brown-Elliott, MS, MT(ASCP)SM Patricia S. Conville, MS, MT(ASCP) Edward P. Desmond, PhD Geraldine S. Hall, PhD Grace Lin, MS Abstract Gaby E. Pfyffer, FAMH, PhD John C. Ridderhof, DrPH Salman H. Siddiqi, PhD Richard J. Wallace, Jr, MD Nancy G. Warren, PhD Frank G. Witebsky, MD This document addresses the susceptibility testing of Mycobacterium tuberculosis complex (MTBC), clinically significant slowly and rapidly growing mycobacterial species, Nocardia spp., and other aerobic actinomycetes. Included in this standard are recommendations for the selection of agents for primary and secondary testing, organism group specific methodologies, reporting recommendations, and quality control criteria for the above-listed organisms. Recommendations regarding the selection of agents for testing mycobacteria are based primarily on guidelines from US agencies. For testing MTBC, M24 recognizes agar proportion as the primary methodology on which all other methodologies are essentially based. This document also includes recommendations for use of commercial broth susceptibility methods with shorter incubation times, which are now in widespread use in the susceptibility testing of MTBC. Clinical and Laboratory Standards Institute (CLSI). Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard Second Edition. CLSI document (ISBN ). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania USA, The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: ; Fax: ; Website:
4 Number 5 Copyright 2011 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, Suggested Citation CLSI. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard Second Edition. CLSI document. Wayne, PA: Clinical and Laboratory Standards Institute; Proposed Standard July 1990 Tentative Standard December 1995 Tentative Standard Second Edition December 2000 Approved Standard April 2003 Approved Standard Second Edition March 2011 ISBN ISSN ii
5 Volume 31 Contents Abstract... i Committee Membership... iii Foreword... vii 1 Scope Standard Precautions Terminology Definitions Abbreviations and Acronyms Antimycobacterial Susceptibility Testing for Mycobacterium tuberculosis Complex Introduction Agar Proportion Method Commercial Broth Systems With Shorter Incubation Time for Susceptibility Testing of Mycobacterium tuberculosis Complex Pyrazinamide Susceptibility Testing Quality Control Implementing New Methods Molecular Detection of Drug Resistance Susceptibility Testing of Nontuberculous Mycobacteria Introduction Preparation of the Inoculum for the Microdilution Method Quality Control Procedures Susceptibility Testing of Mycobacterium avium Complex Susceptibility Testing of Mycobacterium kansasii Susceptibility Testing of Mycobacterium marinum Susceptibility Testing of Miscellaneous Slowly Growing Nontuberculous Mycobacteria Antimycobacterial Susceptibility Testing of Rapidly Growing Mycobacteria Susceptibility Testing of Aerobic Actinomycetes Method Antimicrobial Agents Preparation of the Inoculum Inoculum Suspensions Susceptibility Test Method Reporting of Results Quality Control Table 1. Antituberculous Drugs and Their Recommended Concentrations in Middlebrook 7H10 and 7H11 Agar Medium Table 2. Stock, Working, and Final Concentrations of Antituberculous Drug Solutions for Agar Proportion Table 3. Dilution of Sputum Concentrate for Inoculation of the Susceptibility Test Medium for the Direct Susceptibility Test v
6 Number 5 Contents (Continued) Table 4. Antimycobacterial Agents and Interpretive Criteria for Mycobacterium avium Complex Table 5. Antimycobacterial Agents and Minimal Inhibitory Concentration (MIC) Values Indicating Resistance for Testing M. kansasii Table 6. Antimycobacterial Agents and Minimal Inhibitory Concentration (MIC) Values Indicating Resistance for Susceptibility Testing of Mycobacterium marinum (Routine Testing Is Not Recommended) Table 7. Broth Microdilution Interpretive Criteria for Rapidly Growing Mycobacteria Table 8. Quality Control Ranges of Minimal Inhibitory Concentrations (MICs) (μg/ml) for Mycobacterium peregrinum ATCC , Staphylococcus aureus ATCC 29213, Pseudomonas aeruginosa ATCC 27853, and Enterococcus faecalis ATCC When Testing Rapidly Growing Mycobacteria Table 9. Broth Microdilution Interpretive Criteria for Nocardia and Other Aerobic Actinomycetes.. 43 References Appendix A. Susceptibility Testing of Mycobacterium tuberculosis Complex to Second-line Drugs Using Commercial Shorter Incubation Liquid Media Systems Appendix B. Suggested Approach to Mycobacterium tuberculosis Complex Susceptibility Testing in Resource-Limited Countries Appendix C. Example Illustrating Drug Calculation for Meropenem Trihydrate Appendix D. Preparation and Plating of 7H10 and 7H11 Agar Medium (See Appendixes E and F).. 51 Appendix E. Preparation of Media With Drug-Containing Disks Appendix F. Preparing 7H10/H11 Agar With Liquid Drug Appendix G. McFarland 0.5 Barium Sulfate Turbidity Standard Appendix H. Determining Percentage of Resistance Appendix I. Drugs Available for Susceptibility Testing of Mycobacterium tuberculosis Complex Using Commercial Shorter Incubation Liquid Media Systems Cleared for Use by the US Food and Drug Administration and Their Equivalence in the Agar Proportion Method Appendix J. Agar Disk Elution Method for Mycobacterium haemophilum Appendix K. Expected Antimicrobial Susceptibility Patterns of the Most Commonly Isolated Nocardia The Quality Management System Approach Related CLSI Reference Materials vi
7 Volume 31 Foreword CLSI document M24 was revised based on thoughtful comments from laboratorians involved with regular testing of mycobacteria and/or aerobic actinomycetes, but further refinements are anticipated as more relevant data become available. The document addresses Mycobacterium tuberculosis complex (MTBC), certain nontuberculous mycobacteria (NTM), and Nocardia and other aerobic actinomycetes. Currently, sufficient data exist to support recommendations for susceptibility testing of MTBC, Mycobacterium avium complex (MAC), Mycobacterium kansasii, the rapidly growing mycobacteria, Nocardia spp., and certain other aerobic actinomycetes. The breakpoints for Nocardia and other aerobic actinomycetes are based on organism population distributions, clinical data, breakpoints used for other organisms, and the experience of experts in the field. In tuberculosis (TB), there is generally a mixture of intracellular and extracellular bacilli, as well as actively growing and dormant, metabolically inactive ones. For this reason, pharmacokinetic (PK)/pharmacodynamic (PD) studies have limited ability to predict which drugs will be effective in the treatment of tuberculosis (TB). In fact, it is believed that PK studies would suggest that pyrazinamide should be ineffective against MTBC, when in practice it is a key component of TB treatment. 1 Due to these limitations, experts developed a creative approach to MTBC susceptibility testing, ie, comparing minimal inhibitory concentration (MIC) values of isolates from patients who failed treatment with those of strains never exposed to the anti-tb drug. Clinically resistant strains have higher MIC values, and the wild-type strains, for effective anti-tb drugs, have lower MIC values. The critical concentration is the test concentration that best differentiates these two populations. Follow-up studies showed that testing based on this concept predicted treatment success vs failure for a drug. 1 If, in the future, clinically relevant PK/PD data become available, the information will be included in the document, as appropriate. Laboratory tests for evaluating the susceptibility of mycobacteria and aerobic actinomycetes can confirm the choice of the initial course of chemotherapy and the emergence of drug resistance when a patient fails to show a satisfactory bacteriological response to treatment. Additionally, they can guide the choice of further treatment with different drugs. Susceptibility testing of MTBC can also be used to estimate the prevalence of primary and acquired drug resistance (defined by the World Health Organization 2 as drug resistance among new cases and drug resistance among previously treated patients, respectively) in a community. For each of these purposes, use of a reliable technique to perform the test is essential. Currently, first-line therapy for TB includes isoniazid (INH), rifampin (RMP), ethambutol (EMB), and pyrazinamide (PZA). To ensure that clinicians are provided with comprehensive information regarding this multidrug regimen, initial isolates from all patients should be tested for susceptibility to all four agents. This is a change from the previous edition, which stated that laboratories might consider testing INH, RMP, and EMB only, if their pulmonary and/or infectious disease specialists and TB control officer agree with the reduced panel. Susceptibility testing should be repeated if the patient is culture positive after three months of appropriate therapy or earlier if the patient shows clinical evidence of failure to respond to therapy or is unable to tolerate the initial drug regimen. To ensure the earliest possible detection of resistance, a commercial, shorter incubation system should be used in conjunction with rapid methods for primary culture and identification. In this way, first-line susceptibility test results for most MTBC isolates should be reported within 15 to 30 days of receipt of the specimen in the laboratory. Multidrug-resistant (MDR) TB, although not a major problem in most developed countries, is a serious threat to TB control globally. Recently, the emergence of extensively drug-resistant TB (isolates resistant to the two best first-line agents INH and RMP and the best second-line drugs the fluoroquinolones and either amikacin, kanamycin, or capreomycin), which is associated with extremely poor outcomes and a high mortality rate in patients with concomitant human immunodeficiency virus (HIV) infection, has heightened the concern of global TB control. Consequently, the importance of susceptibility testing to secondary anti-tb drugs has grown. Moreover, drugs other than the traditional secondary agents most importantly the newer fluoroquinolones have been evaluated and shown to be effective additions to the vii
8 Number 5 anti-tb regimen. Given the efficacy and ease of administration, it is anticipated that the use of the newer fluoroquinolones to treat TB will increase in the next several years and, as a result, susceptibility testing of these agents will become more important. Susceptibility testing of NTM and aerobic actinomycetes should be performed on clinically significant isolates 3 (see the paragraph below) that exhibit variability in susceptibility to clinically useful antimicrobial agents and/or significant risk of acquired mutational resistance to one or more of these agents. Because the latter two criteria are not true for Mycobacterium marinum, routine susceptibility testing of this species is not indicated. To determine clinical significance of NTM recovered from respiratory cultures, the American Thoracic Society (ATS) recommends the following criteria: cultures of at least two positive sputum specimens or one bronchial wash or lavage sample are usually sufficient to confirm clinical significance. Alternatively, a transbronchial or lung biopsy with mycobacterial histopathological features and positive culture for NTM is sufficient to establish clinical significance. In addition, isolates from normally sterile sites (such as blood, cerebrospinal fluid, or tissues) typically are considered clinically significant. To facilitate further development of CLSI document M24, the subcommittee requests comments and suggestions for improvement with regard to the methods included herein. All authors of this document donated considerable time to its development; I would like to personally thank all of them for their valuable contributions. Gail L. Woods, MD Chairholder, Subcommittee on Antimycobacterial Susceptibility Testing Note that the trade names BACTEC 460 TB, BACTEC MGIT 960, and VersaTREK are included in either Appendix A and/or Appendix I. It is the Clinical and Laboratory Standards Institute s policy to avoid using a trade name unless the product identified is the only one available, or it serves solely as an illustrative example of the procedure, practice, or material described. In this case, the subcommittee and area committee believe the trade names are used to provide interpretive criteria that are specific to the listed system. These three systems were the only ones cleared by the US Food and Drug Administration at the time this document was completed. Key Words Antimycobacterial drugs, antituberculous drugs, drug susceptibility viii
9 Volume 31 Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard Second Edition 1 Scope CLSI document contains protocols for the susceptibility testing of three major categories of mycobacterial species (Mycobacterium tuberculosis complex [MTBC]; the slowly growing nontuberculous mycobacteria [NTM]; and the rapidly growing mycobacteria) and recommendations for susceptibility testing of Nocardia spp. and miscellaneous aerobic actinomycetes. This document also provides guidance on the selection of primary and, for some organisms, secondary agents for testing and reporting; instructions for performing the standard agar proportion method for MTBC and broth microdilution for NTM; and quality control (QC) protocols for each organism category. Testing and reporting recommendations and principles of QC procedures apply to use of commercial shorterincubation broth systems that have been cleared by the US Food and Drug Administration (FDA) for testing MTBC, as well as the reference methods. 2 Standard Precautions Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to standard precautions. Standard precautions are guidelines that combine the major features of universal precautions and body substance isolation practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the US Centers for Disease Control and Prevention (CDC). 4 For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious diseases, refer to CLSI document M29. 5 The mycobacteriology laboratory presents a unique set of circumstances in terms of observance of biosafety precautions. For more information, it is suggested that the reader refer to Biological Safety: Principles and Practices by Fleming and Hunt. 6 Also, the publication Biosafety in Microbiological and Biomedical Laboratories is now in its fifth edition and is available online at Terminology 3.1 Definitions accuracy (measurement) closeness of agreement between a measured quantity value and a true quantity value of a measurand (ISO/IEC Guide 99). 8 antimicrobial susceptibility test interpretive category a classification based on an in vitro response of an organism to an antimicrobial agent; NOTE 1: For mycobacteria, two different categories, critical concentration and minimum inhibitory concentration, have been used to categorize the in vitro results; NOTE 2: For members of the MTBC, when tested against the lower concentration of some agents, the critical concentration category is applied. Testing of an additional higher concentration may also be recommended for some agents. However, there is no intermediate interpretive category when the critical concentration category is applied, even when testing is performed both at the critical concentration and the additional higher concentration; NOTE 3: For NTM and for the aerobic actinomycetes, only the minimum inhibitory concentration category is applied. Clinical and Laboratory Standards Institute. All rights reserved. 1
10 Number 5 borderline antimicrobial susceptibility test interpretive category an interpretive category applicable only to certain results obtained with MTBC isolates tested against pyrazinamide by the radiometric instrument method (refer to the manufacturer s package insert); NOTE: Repeat testing may determine whether the isolate in question is susceptible or resistant. critical concentration the critical concentrations of antituberculous drugs were adopted by international convention 9 ; NOTE: For each drug, the critical concentration is the lowest concentration that inhibits 95% of wild-type strains of M. tuberculosis that have not been exposed to the drug, but that simultaneously does not inhibit strains of M. tuberculosis considered resistant that are isolated from patients who are not responding to therapy. culture 1) the intentional growing of microorganisms (such as bacteria or viruses) or tissues, in a controlled environment, for purposes of identification or other scientific study, or for commercial and/or medicinal use; 2) the product resulting from the intentional growth of microorganisms or tissue. culture medium a substance or preparation used for the cultivation and growth of microorganisms or tissue. direct susceptibility test a procedure based on inoculation of drug-containing media directly with a processed (concentrated after digestion and decontamination) specimen that is smear-positive for acid-fast bacilli (AFB) to determine the proportion or percentage of resistant MTBC in the patient s bacterial population (see Section 4.2.4). indirect susceptibility test a procedure based on inoculation of drug-containing media using organisms grown in culture (see Section 4.2.3). intermediate antimicrobial susceptibility test interpretive category for minimal inhibitory concentration, an interpretive category that implies that an infection due to the isolate may be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used; also indicates a buffer zone that should prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations. measurand quantity intended to be measured (ISO/IEC Guide 99). 8 minimal inhibitory concentration (MIC) the lowest concentration of an antimicrobial agent that prevents visible growth of a microorganism in a broth dilution susceptibility test. Mycobacterium avium complex (MAC) includes the species M. avium (subspecies avium, colombiense, silvaticum, hominissuis, paratuberculosis) and Mycobacterium intracellulare. Mycobacterium tuberculosis complex (MTBC) includes the species M. tuberculosis, Mycobacterium bovis, M. bovis BCG, Mycobacterium caprae, Mycobacterium pinnipedii, Mycobacterium africanum, Mycobacterium microti, and Mycobacterium canettii. nontuberculous mycobacteria (NTM) all species of mycobacteria other than those in the MTBC. resistant antimicrobial susceptibility test interpretive category 1) For critical concentration, resistance is defined as diminished susceptibility of a strain that differs from wild-type strains from patients who have not been treated with the drug, so that the strain is unlikely to show clinical responsiveness to the drug; 2) For minimal inhibitory concentration, resistant isolates are not inhibited by the usually achievable concentrations of the agent at the site of infection with normal dosage schedules, and/or fall in the range where specific microbial resistance mechanisms are likely (eg, β- lactamases), and clinical efficacy has not been reliable in treatment studies. 2 Clinical and Laboratory Standards Institute. All rights reserved.
11 Number 5 The Quality Management System Approach Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system approach in the development of standards and guidelines, which facilitates project management; defines a document structure via a template; and provides a process to identify needed documents. The approach is based on the model presented in document HS01 A Quality Management System Model for Health Care. The quality management system approach applies a core set of quality system essentials (QSEs), basic to any organization, to all operations in any health care service s path of workflow (ie, operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager s guide. The quality system essentials (QSEs) are as follows: Documents and Records Equipment Information Management Process Improvement Organization Purchasing and Inventory Occurrence Management Customer Service Personnel Process Control Assessments External and Internal Facilities and Safety addresses the quality system essentials (QSEs) indicated by an X. For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page. Documents and Records M07 Organization Personnel Equipment Purchasing and Inventory Process Control X EP12 I/LA18 M02 M07 M22 Information Management Occurrence Management Assessments External and Internal I/LA18 Process Improvement Adapted from CLSI document HS01 A Quality Management System Model for Health Care. Path of Workflow A path of workflow is the description of the necessary steps to deliver the particular product or service that the organization or entity provides. For example, CLSI document GP26 Application of a Quality Management System Model for Laboratory Services defines a clinical laboratory path of workflow that consists of three sequential processes: preexamination, examination, and postexamination. All clinical laboratories follow these processes to deliver the laboratory s services, namely quality laboratory information. addresses the clinical laboratory path of workflow steps indicated by an X. For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page. Examination ordering Customer Service Preexamination Examination Postexamination Sample collection Facilities and Safety Sample transport Sample receipt/processing Examination Results review and follow-up Interpretation Results reporting and archiving M29 Sample management I/LA18 I/LA18 I/LA18 M02 M07 X I/LA18 M02 M07 M100 X I/LA18 M02 M07 M100 Adapted from CLSI document HS01 A Quality Management System Model for Health Care. X M02 M07 M100 X 60 Clinical and Laboratory Standards Institute. All rights reserved.
12 Volume 31 Related CLSI Reference Materials EP12-A2 I/LA18-A2 User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline Second Edition (2008). This document provides a consistent approach for protocol design and data analysis when evaluating qualitative diagnostic tests. Guidance is provided for both precision and method-comparison studies. Specifications for Immunological Testing for Infectious Diseases; Approved Guideline Second Edition (2001). This document addresses specimen collection, handling, and storage, as well as performance criteria for the comparison of immunological test kits and specifications for reference materials. M02-A10 Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard Tenth Edition (2009). This document contains the current Clinical and Laboratory Standards Institute-recommended methods for disk susceptibility testing, criteria for quality control testing, and updated tables for interpretive zone diameters. M07-A8 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard Eighth Edition (2009). This document addresses reference methods for the determination of minimal inhibitory concentrations (MICs) of aerobic bacteria by broth macrodilution, broth microdilution, and agar dilution. M22-A3 Quality Control for Commercially Prepared Microbiological Culture Media; Approved Standard Third Edition (2004). This document contains quality assurance procedures for manufacturers and users of prepared, ready-to-use microbiological culture media. M29-A3 Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline Third Edition (2005). Based on US regulations, this document provides guidance on the risk of transmission of infectious agents by aerosols, droplets, blood, and body substances in a laboratory setting; specific precautions for preventing the laboratory transmission of microbial infection from laboratory instruments and materials; and recommendations for the management of exposure to infectious agents. M100-S21 Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement (2011). This document provides updated tables for the Clinical and Laboratory Standards Institute antimicrobial susceptibility testing standards M02-A10 and M07-A8. CLSI documents are continually reviewed and revised through the CLSI consensus process; therefore, readers should refer to editions. the most current Clinical and Laboratory Standards Institute. All rights reserved. 61
13 950 West Valley Road, Suite 2500, Wayne, PA USA ISBN P: Toll Free (US): F: E:
February 2004 Antiviral Susceptibility Testing: Herpes Simplex Virus by Plaque Reduction Assay; Approved Standard This document provides a protocol for the performance of the plaque reduction assay for
2nd Edition QMS11 Nonconforming Event Management Grounded in the principles of quality management, risk management, and patient safety, this guideline provides an outline and content for developing a program
February 2013 Quality Management System: Development and Management of Laboratory Documents; Approved Guideline Sixth Edition This document provides guidance on the processes needed for document management,
1st Edition POCT06 Effects of Different Sample Types on Glucose Measurements This report provides information to assist the clinical and point-ofcare staff in result and measurement procedure comparisons
1st Edition QMS16 Laboratory Personnel Management This guideline describes the process for meeting the regulatory and accreditation requirements of personnel management in the laboratory environment. This
March 2010 Accuracy in Patient and Sample Identification; Approved Guideline This guideline describes the essential elements of systems and processes required to ensure accurate patient identification.
October 2011 EP23-A Laboratory Quality Control Based on Risk Management; Approved Guideline This document provides guidance based on risk management for laboratories to develop quality control plans tailored
January 2011 Clinical Laboratory Waste Management; Approved Guideline Third Edition Based on US regulations, this document provides guidance on the safe handling and disposal of chemical, infectious, radioactive,
February 2009 Training and Competence Assessment; Approved Guideline Third Edition This document provides background information and recommended processes for the development of training and competence
August 2012 Verification of Comparability of Patient Results Within One Health Care System; Approved Guideline (Interim Revision) This document provides guidance on how to verify comparability of quantitative
March 2010 Gas Chromatography/Mass Spectrometry Confirmation of Drugs; Approved Guideline Second Edition This document provides guidance on establishing uniform practices necessary to produce quality data
December 2008 Performance Metrics for Continuous Interstitial Glucose Monitoring; Approved Guideline This document provides consensus guidelines for health care professionals, in vitro diagnostic (IVD)
1st Edition QMS18 Process Management This guideline describes four requirements for managing laboratory processes and provides suggestions for effectively meeting regulatory and accreditation requirements,
Overview of Tuberculosis Epidemiology, Transmission, Clinical Presentation, and Treatment Tuberculosis Airborne disease caused by the bacterium Mycobacterium tuberculosis (M. tb) M. tb complex (MTBC) includes
I. INTENDED USE BACTEC MGIT 960 SIRE Kit For the Antimycobacterial Susceptibility Testing of Mycobacterium tuberculosis The BACTEC MGIT 960 SIRE Kit is used as a rapid qualitative procedure for susceptibility
ISBN 1-56238-584-4 Volume 25 Number 27 ISSN 0273-3099 Interference Testing in Clinical Chemistry; Approved Guideline Second Edition Robert J. McEnroe, PhD Mary F. Burritt, PhD Donald M. Powers, PhD Douglas
ISBN 1-56238-475-9 ISSN 0273-3099 Gas Chromatography/Mass Spectrometry (GC/MS) Confirmation of Drugs; Approved Guideline Volume 22 Number 22 Larry D. Bowers, Ph.D., DABCC, Chairholder David A. Armbruster,
Tuberculosis Rapid diagnostics of tuberculosis and its resistances Our molecular test systems allow for an efficient and subsequent detection of MDR or XDRTB. FluoroType MTB is the innovative test system
Vol. 27 No. 26 Replaces H3-A5 Vol. 23 No. 32 Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture; Approved Standard Sixth Edition This document provides procedures for the collection
Vol. 28 No. 20 Replaces H47-A Vol. 16 No. 3 One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test; Approved Guideline Second Edition This document provides guidelines
December 2014 Planning for Laboratory Operations During a Disaster; Approved Guideline This document provides guidance for laboratory and health care leadership for development, implementation, and sustainment
Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges John B. Kaneene, DVM, MPH, PhD University Distinguished Professor of Epidemiology Director, Center for Comparative Epidemiology
What is the Hain Genotype MTBDRplus and how does it work? The Genotype MTBDRplus test is a WHO-endorsed line-probe assay (LPA) for the rapid detection of Mycobacterium tuberculosis complex (MTB) and mutations
Fact sheet: cepheid xpert mtb/rif assay November 2013 Laboratory Considerations for Use of Cepheid Xpert MTB/RIF Assay This document is intended to guide laboratories on integrating the Cepheid Xpert MTB/RIF
NON-COMMERCIAL CULTURE AND DRUG-SUSCEPTIBILITY TESTING METHODS FOR SCREENING OF PATIENTS AT RISK OF MULTI-DRUG RESISTANT TUBERCULOSIS - POLICY STATEMENT - July 2010 TABLE OF CONTENTS 1. Background... 1
Surgery for MDR/XDR Tuberculosis and Non-Tuberculous Mycobacterial Disease John D. Mitchell, M.D. Professor and Chief Section of General Thoracic Surgery Davis Endowed Chair in Thoracic Surgery University
Vol. 27 No. 4 Replaces H20-A Vol. 12 No. 1 Reference Leukocyte (WBC) Differential Count (Proportional) and Evaluation of Instrumental Methods; Approved Standard Second Edition This document is a reference
TB Prevention, Diagnosis and Treatment Accelerating advocacy on TB/HIV 15th July, Vienna Diagnosis Microscopy of specially stained sputum is the main test for diagnosing TB (1 2 days) TB bacilli seen in
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention National Center for HIV, STD, and TB Prevention Division of Tuberculosis Elimination Public
ISBN 1-56238-460-0 ISSN 0273-3099 Implementing a Needlestick and Sharps Injury Prevention Program in the Clinical Laboratory; A Report Volume 22 Number 4 M. Clare Edelmayer, M.T.(ASCP), R.N., M.S. Beverly
CHAPTER 13 Quality Control/Quality Assurance Quality Control/Quality Assurance (QC/QA) can be defined as the set of planned and systematic activities focused on providing confidence that quality requirements
Tuberculosis Exposure Control Plan for Low Risk Dental Offices A. BACKGROUND According to the CDC, approximately one-third of the world s population, almost two billion people, are infected with tuberculosis.
Journal of Antimicrobial Chemotherapy (2002) 50, 1045 1049 DOI: 10.1093/jac/dkf211 Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both
Advances in Laboratory TB Diagnosis Adam J. Caulfield, Ph.D. Columbus, OH September 29, 2015 2014 MFMER slide-1 Disclosures None 2014 MFMER slide-2 Learning Objectives How mycobacteria are grown and identified
COUNCIL OF THE EUROPEAN UNION Brussels, 22 May 2008 9637/08 SAN 88 DENLEG 52 VETER 7 NOTE from: Committee of Permanent Representatives (Part 1) to: Council No. prev. doc.: 9392/08 SAN 77 DENLEG 48 VETER
MODULE THREE TB Treatment Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be covered TB treatment fundamentals Treatment of TB infection and disease TB treatment research Advocacy issues 2 Section
CHAPTER 4: BASIC FACTS ABOUT TUBERCULOSIS (TB) 4.1 Etiology... 2 4.2 Characteristics of TB Bacteria...3 4.3 Signs and Symptoms of Active TB Disease..... 3 4.4 Transmission....4 4.5 Disease Process (Pathogenesis).....
Laboratory Procedure BD Affirm VPIII Ambient Temperature Transport System For collection and extended transport of vaginal specimens for use in the Affirm VPIII Microbial Identification Test. I. INTENDED
ATTEMPT OF MYCOPLASMA ISOLATION RATE DETERMINATION FROM BOVINE RESPIRATORY DISEASES IN EUROPE FROM 2002 Vallé M., Galland D., Broissier M., Woehrlé F., Boisramé B. Vetoquinol Research Centre Corresponding
Guidance for Industry Pulmonary Tuberculosis: Developing Drugs for Treatment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
Diagnosis of Tuberculosis Lisa Y. Armitige, MD, PhD Medical Consultant Heartland National TB Center Associate Professor Internal Medicine/Pediatrics University of Texas HSC Tyler Outcomes of Exposure to
Performance Evaluation and Clinical Application of MTB NAAT in Orange County, CA Minoo Ghajar Orange County Public Health Laboratory TB Case Count and Rate: Orange County, CA and the United States, 2012
Chapter 105 Management of Tuberculosis: Indian Guidelines Kuldeep Singh Sachdeva INTRODUCTION Tuberculosis (TB) is an infectious disease caused predominantly by Mycobacterium tuberculosis and among the
Chapter 1 Overview of Tuberculosis Epidemiology in the United States Table of Contents Chapter Objectives.... 1 Progress Toward TB Elimination in the United States.... 3 TB Disease Trends in the United
Tuberculosis Contents Epidemiology in New Zealand 2 Case definition 2 Clinical description 2 Laboratory test for diagnosis 3 Case classification 3 Spread of infection 4 Incubation period 4 Mode of transmission
Doing the Math: The Dilemma of Drug Resistant Tuberculosis Frances Jamieson, MD, FRCPC PHO Rounds, April 17 th, 2012 Tuberculosis : A Global Problem WHO Estimates (2010 data): 8.8 million New Infections
Frequently Asked Questions on Xpert MTB/RIF assay Contents How does the test work?... 2 How was the Xpert MTB/RIF test developed?... 2 What is the public health significance?... 2 What does it cost?...
CHECKLIST OF FOR THE USE OF LIQUID MEDIA FOR CULTURE AND DRUG SUSCEPTIBILITY TESTING (DST) Rationale for liquid culture systems Laboratory diagnosis of tuberculosis (TB) relies on the direct microscopic
Whole Genome Sequencing for TB Diagnostics at the Wadsworth Center. May 19, 2015 Kimberlee Musser, PhD Chief, Bacterial Diseases May 19, 2015 2 TB Background Tuberculosis is an ancient disease that has
Mississippi Downloaded 01/2011 101.11 Infectious Medical Waste. The term "infectious medical waste" includes solid or liquid wastes which may contain pathogens with sufficient virulence and quantity such
Section E.3 University of South Carolina Safety Program Guide BLOODBORNE PATHOGENS Introduction The Occupational Safety and Health Administration (OSHA) established the regulatory standard 29 CFR 1910.1030,
TB Treatment: To Cure and Protect Session Three of a Four-Part Webinar Series Presented in Partnership with the BC Lung Association Facilitators: Nash Dhalla, Program Coordinator & Nurse Consultant, TB
7- Master s Degree in Public Health and Public Health Sciences (Majoring Microbiology) Students should fulfill a total of 38 credit hours: 1- Basic requirements: 10 credit hours. 150701, 150702, 150703,
Biosafety in the Mycobacteriology Laboratory Thomas M. Shinnick, Ph.D. Mycobacteriology Laboratory Branch Division of Tuberculosis Elimination SAFER HEALTHIER PEOPLE Why is Biosafety Needed in the Mycobacteriology
Policy Directive Ministry of Health, NSW 73 Miller Street North Sydney NSW 2060 Locked Mail Bag 961 North Sydney NSW 2059 Telephone (02) 9391 9000 Fax (02) 9391 9101 http://www.health.nsw.gov.au/policies/
Request for Applications: Evaluation of PZA Inoculum Testing Methods for Mycobacterium tuberculosis complex Application Due Date: January 7, 2015 Submit to: William Murtaugh, Specialist, TB Program (email@example.com).
Tuberculosis Course Health Science Unit VIII Strategies for the Prevention of Disease Essential Question How does tuberculosis infect the body? TEKS 130.204 (c) 1F, 12A, 12B, 12C Prior Student Learning
Screening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults) H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg
Appendix B. Tuberculosis (TB) risk assessment worksheet This model worksheet should be considered for use in performing TB risk assessments for healthcare facilities and nontraditional facility-based settings.
Section III Principles of Biosafety A fundamental objective of any biosafety program is the containment of potentially harmful biological agents. The term containment is used in describing safe methods,
Sterilization, Disinfection, and Decontamination Decontamination & Cleaning Decontamination renders an item or material safe to handle. The level of microbial contamination is reduced enough that it can
Contents Infection Prevention and Control Infection Prevention & Control Measures for Patients with Pulmonary Policy... 1 Purpose... 1 Scope/Audience... 1 Associated documents... 1 1.1 Use of Transmission-based
PRIORITY RESEARCH TOPICS Understanding all the issues associated with antimicrobial resistance is probably impossible, but it is clear that there are a number of key issues about which we need more information.
TUBERCULOSIS INTRODUCTION Tuberculosis is an infectious disease caused by a bacterium, myobacterium tuberculosis. The disease is spread when people inhale droplets of saliva or mucous from infected people.
X-Plain Pediatric Tuberculosis Reference Summary Introduction Tuberculosis, or TB, is a bacterial infection that causes more deaths in the world than any other infectious disease. When a child gets TB,
UNIVERSITÄTSKLINIK FÜR INNERE MEDIZIN I Abteilung für Infektionen und Chemotherapie Mikrobiologische Laboratorien 3P Univ. Prof. DDr. A. Georgopoulos Währinger Gürtel 18-20, A - 1090 Wien, Austria Tel.:
Original Article 75 CAN CORD FORMATION IN BACTEC MGIT 960 MEDIUM BE USED AS A PRESUMPTIVE METHOD FOR IDENTIFICATION OF M. TUBERCULOSIS COMPLEX? Mugdha Kadam, Anupama Govekar, Shubhada Shenai, Meeta Sadani,
2013 Indiana Healthcare Provider and Hospital Administrator Multi-Drug Resistant Organism Survey Antibiotic resistance is a global issue that has significant impact in the field of infectious diseases.
Self-Study Modules on Tuberculosis Treatment of Latent Tuberculosis Infection and Tube rc ulos is Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National
Table of Contents Education and Training Yale New Haven Health System Center for Healthcare Solutions 2009-2010 Fall/Winter Course Guide TOPICS firstname.lastname@example.org www.yalenewhavenhealth.org/healthcaresolutions
Doctor of Philosophy Program in Microbiology FACULTY OF MEDICAL SCIENCE Naresuan University 171 Doctor of Philosophy Program in Microbiology The time is critical now for graduate education and research
CANADIAN RULE BASED CLASSIFICATION SYSTEM (IVDD) Life Sciences British Columbia NRC-Industry Research Assistance Program Health Canada Regulations on Medical Devices Vancouver, B.C. October 29, 2007 Nancy
DST proficiency testing rounds in the Supranational Reference Laboratory Network Armand Van Deun The Union & Antwerp coordinating SRL SRL network Grown to 32 laboratories (18th round, 2011) 4 new SRL recently
MANAGEMENT OF TUBERCULOSIS Dean B. Ellithorpe, M.D. Clinical Professor of Medicine Section of Pulmonary Diseases, Critical Care and Environmental Medicine Tulane University School of Medicine INTRODUCTION
Disc Diffusion Susceptibility Methods Introduction When a filter paper disc impregnated with a chemical is placed on agar the chemical will diffuse from the disc into the agar. This diffusion will place
Sutter Health Support Services Shared Laboratory Position Description Position Title: Clinical Laboratory Scientist, Microbiologist Incumbent: Entity: SHSS Shared Laboratory Reports To: Director of Operations,
TUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY Stephanie N. Lin MD 2/12/2016 Epidemiology of TB 9.6 million new cases in 2014 12% of them are in HIV positive patients 1.5 million deaths in 2014 ~646
UNIVERSITY OF OTTAWA OCCUPATIONAL HEALTH, DISABILITY AND LEAVE SECTOR MEASURES TO MINIMIZE EXPOSURE TO BLOODBORNE PATHOGENS AND POST-EXPOSURE PROPHYLAXIS POLICY Prepared by the Occupational Health, Disability